Figure 1 Venomous snakes

Slides:

Advertisements

Similar presentations

 Brown snake venom contains potent toxins in venom that cause paralysis or muscle weakness. Also present are postsynaptic neurotoxins, which are less.

Advertisements

Figure 1 Incidence and mortality of cutaneous melanoma

Figure 3 Life expectancy at birth in all countries included

Figure 1 Anatomy of the spinal column

Figure 2 The US Centers for Disease Control and

Reproduced with permission from Yancy, C. W. et al. 2017

Figure 8 Implanted devices for the management of heart failure

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Global epidemiology of common Clostridium difficile ribotypes

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 7 European Society of Cardiology 2016

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Cardiology is replete with examples of fractal structures

Effectiveness of A Clinical Protocol Implemented To Standardize Snakebite Management In Iran: Initial Evaluation Seyed Mostafa Monzavi, MD, Amir Ahmad.

Creating A Snakebite Order Set (Blank Template Example) Customize Your Order Set to the Type of Snakebites You See and to Your Patient Population.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Imaging methods used to study Parkinson disease

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 1 Decision tree integrating the assessment,

Figure 2 Incidence of multiple myeloma in 2012

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Global cost of HF per capita in 2012

Figure 3 Genetic pleiotropy in ALS

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Stroke-related deaths and DALYs by country development status

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 Potential interplay between physiological

Figure 12 Cardiac gossypiboma

Nat. Rev. Nephrol. doi: /nrneph

Figure 8 HRQOL in individuals with RA

Figure 4 Diagnosing neuropathic pain

Figure 1 Structure of ADAMTS13

Figure 2 Dzyaloshinskii–Moriya interactions

Adapted with permission from Tesfaye, S. , Boulton, A. J

Figure 9 Management of atrial fibrillation

Nat. Rev. Nephrol. doi: /nrneph

Volume 393, Issue 10167, Pages (January 2019)

Figure 2 Global mortality and incidence rates of pancreatic cancer

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Global kidney cancer incidence

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 6 Schematic diagram of the CAT system

Figure 1 Worldwide prevalence of MRSA

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Determination of the primary site

Figure 4 Treponema pallidum invasion

Figure 5 Algorithm for the management of hypertension

Figure 1 Treponema pallidum

Figure 2 Diffusio-osmotic process for osmotic energy conversion

Figure 4 Clinical manifestations of alopecia areata

Part b is reproduced with permission from Messenger, A. G

Presentation transcript:

Figure 1 Venomous snakes Images b–h courtesy of D.A.W., University of Oxford, UK, and image i courtesy of D.J.W., University of Melbourne, Victoria, Australia Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi:10.1038/nrdp.2017.63

Figure 2 Geographical distribution of the estimated number of snakebite envenomings and deaths Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi:10.1038/nrdp.2017.63

Figure 3 Toxin levels in the venom of viperids and elapids Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi:10.1038/nrdp.2017.63

Figure 4 Immunoaffinity capturing antivenomics protocol Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi:10.1038/nrdp.2017.63

Figure 5 Action of snake venom toxins on different body systems Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi:10.1038/nrdp.2017.63

Figure 6 Clinical effects of snake venoms. Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi:10.1038/nrdp.2017.63